

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in *EGFR*-Mutant NSCLC

Xiuning Le, Sonam Puri, Marcelo V. Negrao, et al.

Clin Cancer Res 2018;24:6195-6203. Published OnlineFirst September 18, 2018.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-18-1542](https://doi.org/10.1158/1078-0432.CCR-18-1542)

Supplementary Material Access the most recent supplemental material at:
<http://clincancerres.aacrjournals.org/content/suppl/2018/09/18/1078-0432.CCR-18-1542.DC1>

Cited articles This article cites 32 articles, 10 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/24/24/6195.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/24/24/6195.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/24/24/6195>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.